| Drug Name |
Tirofiban |
| Drug ID |
BADD_D02228 |
| Description |
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. |
| Indications and Usage |
For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. |
| Marketing Status |
approved |
| ATC Code |
B01AC17 |
| DrugBank ID |
DB00775
|
| KEGG ID |
D08607
|
| MeSH ID |
D000077466
|
| PubChem ID |
60947
|
| TTD Drug ID |
D0BN9X
|
| NDC Product Code |
68083-145; 25208-001; 25208-002; 55150-430; 55150-429; 25208-901; 25208-902 |
| UNII |
GGX234SI5H
|
| Synonyms |
Tirofiban | N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine | Aggrastat | Agrastat | MK 383 | MK-383 | L 700462 | L-700462 | L-700,462 | L 700,462 | L700,462 | Tirofiban Hydrochloride | Tirofiban Hydrochloride Monohydrate |
